Molteni Farmaceutici is one of the centers of excellence in European production and is the market leader for the production and marketing of opioid drugs. The company is engaged in research and manufacture of therapeutic solutions for the treatment of pain and addiction in defense of the quality of life and care of patients. A solid past behind, awareness of their value and the ability to look to the future with determination have made Molteni Farmaceutici an excellent Tuscan and Florentine and global player on the drug market for more than a century.
Contact
Tel. + 39 055 73611
Address: Strada Statale, 67 Fraz. Granatieri, Scandicci (FI) ) Italy
Web: moltenifarma.it
In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s…
Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market. …
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
Pierluigi Petrone outlines family-owned Petrone Group’s wide-range of outsourcing services to the pharmaceutical industry, how its international footprint has evolved over time, and his key priorities as president of Italy’s…
Organon Italy’s Alper Alptekin introduces the newly formed women’s health company, his priorities for the Italian affiliate, and how improvements in women’s health can improve gender equality and give women…
Bormioli Pharma’s Andrea Lodetti outlines the company’s evolution towards becoming an international leader in the pharma and primary packaging business, COVID-related business impacts, the shift towards localised manufacturing, and the…
Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of…
Claudia Coscia outlines how the geographic and portfolio transformation of Kyowa Kirin has played out in Italy in recent years. Coscia also touches on access challenges for rare disease therapies…
See our Cookie Privacy Policy Here
